1.. Introduction
================

Sarcoidosis is a chronic, inflammatory, systemic disease affecting primarily the lungs, the mediastinum and the lymphatic system but also salivary glands, heart, nervous system, joints and various other organs ([@b1-ol-0-0-7247]). Diagnosis depends on the existence of typical clinicoradiological findings in association with noncaseating epitheloid cell granulomas in biopsy and the absence of known, alternative or local causes provoking granulomas ([@b1-ol-0-0-7247]). Granulomas are nonspecific inflammatory lesions and can occur during mycobacterial, fungal or parasitic infections as well as other diseases like Wegener\'s granulomatosis ([@b2-ol-0-0-7247]). Due to the differentiation of granulomas the pathologists play a pivotal role in finding the correct diagnosis ([@b2-ol-0-0-7247]). In sarcoidosis, granuloma formation is characterized by infiltrating Th1 helper cells and macrophages. The latter show a transformation process into epitheloid cells and can fuse into multinucleate giant cells. Although small amounts of necrosis can be observed, the sarcoid granuloma is referred to the group of nonnecrotizing or noncaseating granulomas ([@b2-ol-0-0-7247]). Caseating granulomas are typically found in infectious diseases like syphilis or tularemia or infection with tuberculous and nontuberculous mycobacterium ([@b2-ol-0-0-7247]). In some, especially oncologic patients treated with immunotherapy, noncaseating granulomas can be found although they do not fulfill the criteria for systemic sarcoidosis and are thus referred to as sarcoid-like reactions ([@b3-ol-0-0-7247]). Due to the toxicity profile of immunotherapies immune-related adverse events can provoke those sarcoid-like reactions which may occur in the organ of tumor origin or in the tumor-draining lymph nodes ([@b3-ol-0-0-7247]). Sarcoidosis is associated with an increased risk for cancer development in several organs like lung, liver, stomach or for melanoma and lymphoma. Sarcoid-like reactions can be found in 13.8% of patients with Hodgkin-disease, 7.3% with non Hodgkin lymphoma and 4.4% of cases with carcinomas ([@b4-ol-0-0-7247],[@b5-ol-0-0-7247]). Furthermore, simultaneous occurrence of sarcoidosis and cancer is associated with a diminished survival rate ([@b6-ol-0-0-7247]). Although no increased risk for malignancy in the head and neck has been described so far, there are a few cases that report the simultaneous occurrence of sarcoidosis and malignoma of the head and neck ([@b7-ol-0-0-7247]--[@b9-ol-0-0-7247]). Notably, in follow-up computed tomography (CT) scans or those done for the detection of primary tumors or metastatic lesions (e.g., 18-Fluorodeoxyglucose positron emission tomography-(PET)-CT, ^18^FDG-PET-CT) sarcoidosis can mimic cancer recurrence or metastatic progress ([@b10-ol-0-0-7247],[@b11-ol-0-0-7247]). However, it is possible that metastatic lesions coexist next to lymph nodes with sarcoid-like lesions and it is unclear whether sarcoidosis has an influence on metastasis of malignoma. Therefore, a review of the current literature was performed to analyze the residual risk of metastasis within radiological suspicious lesions in patients with a history of solid tumors and sarcoidosis.

2.. Methods
===========

In this review we analyzed reported cases of patients with solid tumors whose staging or follow-up analysis revealed an unclear lymphadenopathy owing to metastasis or sarcoidosis. A systematic literature search was done in Pub Med data base (from inception to April 2017) without any limitation using the terms: Sarcoidosis \[title\] AND metastasis. All cases with a solid tumor and sarcoidosis were included and the provided information concerning age, gender, tumor region, tumor entity, tumor classification, therapy, as well as information about diagnosis of sarcoidosis were collected. Analyzing the data, the risk of simultaneous occurrence of metastasis and sarcoidosis in concordance to positive radiological and histological findings was elucidated.

Ethical approval
================

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent: Informed consent was obtained from all individual participants included in the study. This article does not contain any studies with animals performed by any of the authors. For this retrospective study and review of anonymized clinical records an ethical permission was not required.

3.. Results
===========

### Review of the literature

Review of the literature revealed 115 cases in Pub Med Data Base based on the search criteria mentioned above. Cases without malignancy were excluded and 59 cases with cancer and sarcoidosis were identified and are listed in [Table I](#tI-ol-0-0-7247){ref-type="table"}. The median age at cancer diagnosis was 49.5 +/- 13.4 years and cases of 31 female and 23 male patients were reported. In 5 cases, the sex of the patient was not documented. Systemic sarcoidosis treatment consisted of oral steroids (n=12) or chloroquine (n=1). Local steroids were applied in one case with uveitis. No therapy was initiated in 15 cases and 30 cases did not provide any information about the sarcoidosis therapy approach. However, independent from the treatment strategy the patients\' outcome was described to be good with a stable status or complete remission. The most frequent cancer origin was breast (n=12) followed by malignoma of the thyroid gland (n=8). Sarcoidosis occurred in 20 cases after an average of 34.4 months and in 7 cases 10.25 years before diagnosis of malignoma. In most reported cases (n=24) sarcoidosis was revealed simultaneously with diagnosis of malignoma. In 25 cases, surgery was performed to remove the tumor. 24 patients had a combination of surgery and radio-, chemo- or radiochemotherapy. Two cases were only treated by radiochemotherapy and in seven cases, no information about therapeutic aspects concerning the tumor was provided. Occurrence of sarcoidosis after surgery was reported in 3/25 cases and in 17/24 cases after surgery and radio-/chemotherapy. In 17% of the cases, simultaneous detection of sarcoidosis or sarcoid-like lesions and metastasis was reported (n=10). These reports are now described in more detail.

The first case describes a 50-year-old female patient suffering from ductal invasive breast carcinoma with local lymph node metastasis (pT3pN1). Chest X-ray and ^18^FDG-PET-CT were performed for staging of the tumor and showed a bilateral mediastinal lymphadenopathy and an increased FDG-uptake in supra-diaphragmatic and pelvic lymph nodes. Biopsy of an example lesion obtained sarcoidosis ([@b12-ol-0-0-7247]). Secondly, an 80-year-old female\'s CT scan revealed a tumor suspicious mass in the upper lobe of the right lung, multiple smaller nodules and hilar lymphadenopathy. Subsequent biopsy of the mass and a mediastinal lymph node showed just noncaseating granulomas but no malignant cells and led to insufficient treatment. Six months later, symptoms like cough and chest pain were exacerbated and a thoracocentesis revealed adenocarcinoma cells. Further staging examination showed pleural, pericardial and diaphragmatic metastasis. Due to tumor progress, palliative care was initiated ([@b13-ol-0-0-7247]). The third case describes a 57-year-old female patient who was found to have a choroidal mass in the left eye. Total body gallium 67 scan showed an increased uptake in salivary and lacrimal glands and was misinterpreted as typical for sarcoidosis. Progress of symptoms resulted in enucleation and revealed a choroideal metastasis of a papillary lung carcinoma ([@b14-ol-0-0-7247]). Sato *et al* ([@b15-ol-0-0-7247]) report on a patient with concomitant sarcoidosis and lung adenocarcinoma. Thoracoscopic biopsy of altered lymph nodes did not detect metastasis but sarcoidosis. Surgery was performed and a permanent pathological slide showed that several nodes contained both sarcoidosis and lung cancer metastasis ([@b15-ol-0-0-7247]). Three other reports describe patients suffering from papillary thyroid carcinoma that underwent thyreoidectomy and modified neck dissection. Pathology revealed concurrent existence of sarcoidosis and regional lymph node metastasis ([@b10-ol-0-0-7247],[@b16-ol-0-0-7247],[@b17-ol-0-0-7247]). One patient (27-year-old, male) shows a papillary thyroid carcinoma upon a previously diagnosed sarcoidosis. Local lymph nodes contained sarcoidosis mixed with metastasis. A 35-year-old male with a previous history of melanoma developing metastatic involvement and sarcoidosis in regional lymph nodes was described by Chaigne *et al* ([@b18-ol-0-0-7247]). Khan and Khan ([@b19-ol-0-0-7247]) described a 52-year-old patient with cough and chest pain. Radiologic examination showed bilateral hilar lymphadenopathy. Furthermore, within a biopsy of an enlarged lymph node, a metastasis of a left kidney hypernephroma was detected ([@b19-ol-0-0-7247]).

Taken together, these ten patients had a median age of 49 years ranging from 27 to 80 years at the time point of simultaneous detection of metastasis and sarcoidosis. The gender ratio was 0.6:1 (male to female) although no information concerning the sex was provided in two cases. In 8 cases (80%), the metastases were localized in regional lymph nodes whereas just 2 cases showed distant metastases. Furthermore, the region and entity of the associated tumor differed greatly (breast: n=1, lung: n=3, thyroid: n=4, skin: n=1, kidney: n=1).

4.. Discussion
==============

### Sarcoidosis and metastasis

Although there are several published cases concerning coexistence of malignoma and sarcoidosis, the causal relationship between these entities is still unclear. On the one hand, it is possible that patients with sarcoidosis develop malignancies and, on the other hand, there are oncologic patients developing sarcoidosis and sarcoid-like reactions, especially after chemotherapy ([@b3-ol-0-0-7247]). Several cases describe a mimicking of metastatic disease by sarcoidosis but just a few cases actually report a simultaneous occurrence of sarcoidosis and metastases.

Active sarcoidosis is characterized by an enhanced local expression of T helper 1 (Th1) and T helper 17 (Th17) chemokines and cytokines like IFN-γ, TNF-α, IL-17A and IL-22. In various chronic, autoimmune, inflammatory diseases, such as sarcoidosis, the percentage of IL-17A^+^/IFN-γ^+^ double-producing Th-cells is increased in peripheral blood and is related to high disease activity. Furthermore, in these pathological conditions, a dysfunctional response of regulatory T-cells (Tregs) has been described that is characterized by an insufficient immunosuppressive function ([@b20-ol-0-0-7247]). Interestingly, cytotoxic T-lymphocyte antigen 4 (CTLA-4) expression is decreased while PD-1 (programmed death-1) expression is increased in Th17-cells in the mediastinal lymph nodes during sarcoidosis ([@b20-ol-0-0-7247]). CTLA-4 is present on Th-cells and mediates an inhibitory effect on further T cells responses. Hence, a diminished CTLA-4 level maintains inflammatory reactions. Similarly, PD-1 is expressed on the surface of T-cells upon activation and is involved in limiting inflammatory reactions ([@b21-ol-0-0-7247]). Its ligand, PD-1L, can be found on tumor cells and provokes upregulation of PD-1 in T cells. Consequently, activation of tumor antigen-specific T-cells in pancreatic adenocarcinoma is inhibited ([@b22-ol-0-0-7247]). Hence, the bivalent adaptive immune response in patients with sarcoidosis and metastasis promotes both pathological conditions by maintaining sarcoidosis-related inflammation due to the decreased anti-inflammatory CTLA-4 expression while limiting tumor-specific T cell activation, marked by an increased PD-1 expression, that enables tumor escape from the immune system and metastasis. Increased PD-1 expression on T-cells in sarcoidosis lymph nodes could thus be a possible predictor of metastasis on the basis of sarcoidosis. Furthermore, myeloid-derived suppressor cells (MDSC) might play a pivotal role in the pathogenic association between sarcoidosis and metastasis. MDSC pursue immunoregulatory and T-cell suppressive functions ([@b23-ol-0-0-7247]). Although it has not been described yet, an influence of MDSC on sarcoidosis is assumable because of their important role in other inflammatory diseases ([@b24-ol-0-0-7247]). Th-17 cells are the main source of IFN-γ production in sarcoidosis and IFN-γ induces MDSC differentiation and promotes their immunosuppressive function ([@b20-ol-0-0-7247],[@b25-ol-0-0-7247]). In cancer models, MDSC accumulation was promoted by several cytokines and growth factors, such as IL-6, IL-1ß and S100A8/A9, resulting in an anti-inflammatory tumor microenvironment ([@b23-ol-0-0-7247]). MDSC themselves express cytokines and chemokines like IL-6, TNF, IL-1β, IL-23 and S100A9 and have the potential to attract both further myeloid cells and tumor cells ([@b26-ol-0-0-7247]). Furthermore, in a melanoma and lung carcinoma mouse model, S100A9 expressing MDSC were identified as important players in enabling tumor metastasis ([@b27-ol-0-0-7247]). Consequently, they are generally recognized as dominant tumor-promoting forces ([@b28-ol-0-0-7247]). Patients suffering from sarcoidosis have increased serum levels of S100A8/A9 and an enhanced cytoplasmatic S100A8/A9 expression in monocytes and multinuclear giant cells in granulomas ([@b29-ol-0-0-7247]). Because of the sarcoidosis-related inflammation, marked by the expression of IFN-γ, IL-6, IL-23 and S100A8/A9, we can suspect a similar microenvironment to tumors that are characterized by an increased accumulation and immunosuppressive function of MDSC. Accordingly, we can assume that sarcoidosis has the potential to promote metastasis by inducing tumor-promoting and immune-regulating cell subsets. Further analysis is necessary to verify the influence of MDSC on sarcoidosis as well as the cellular immune response concerning the association between sarcoidosis and metastasis.

### Differentiation between benign and malignant lesions

PET-CT scan is a very useful diagnostic tool to identify malignant lesions with a sensitivity between 47 and 100% and a specificity of 86--100% ([@b30-ol-0-0-7247]). Unfortunately, elevated FDG uptake can also be detected in inflammatory diseases such as sarcoidosis causing a diagnostic dilemma. The case of a 61-year-old carpenter with a history of adenocarcinoma of the paranasal sinus and simultaneous occurrence of multiple cervical metastases and sarcoidosis detected during follow-up investigation impressively demonstrates the risk to overlook metastatic lesions within sarcoidosis ([Fig. 1](#f1-ol-0-0-7247){ref-type="fig"}). Especially PET scans for staging or restaging of oncologic diseases supply important information about tumor progression. Decisions on curative or palliative therapy are based on this information, emphasizing the importance to avoid misdiagnosis. Inclusion of an additional tracer would be helpful to differentiate between inflammation and tumor. F18-labeled 3′deoxy-3′fluorothymidine (FLT) is such a promising tracer to minimize diagnostic and subsequent therapeutic mistakes. By measuring DNA synthesis instead of metabolic activity that seems to be more specific to detect tumor diseases, FLT might be a useful candidate to discriminate between tumor and sarcoidosis lesions ([@b7-ol-0-0-7247]).

An additional helpful tool to discriminate inflammatory bone marrow involvement, like skeletal sarcoidosis, from metastatic disease might be the diffusion whole-body magnetic resonance imaging (b-values 50--900s/mm^2^). In contrast to malignant lesions (cut-off value of 774 µm^2^/s), sarcoidosis or other inflammatory skeletal reactions show high signal intensity on diffusion-weighted images and a lower apparent diffuse coefficient (ADC) ([@b12-ol-0-0-7247]).

Bioptical evaluation of radiologically altered lymph nodes is necessary for selection of appropriate oncological treatment strategy. However, examination of each PET-CT positive lesion is not feasible and the chance to detect metastatic lesions next to sarcoidosis is rather rare ([Fig. 2](#f2-ol-0-0-7247){ref-type="fig"}). Thus, even if pathological findings were suspicious of sarcoidosis, concomitant metastasis cannot be certainly excluded. Hence, correlation between the radiological and histological findings with the probability of distant or local metastasis corresponding to the tumor entity is important for the careful assessment of the residual metastasis risk.

5.. Conclusion
==============

Correlation between PET-Scan, histological findings and knowledge about typical tumor behavior is necessary to avoid misdiagnosis. Nevertheless, a residual risk of overlooking metastases in systemic inflammatory diseases still remains existent. Therefore, it is important for clinical practice to be aware of the simultaneous occurrence of sarcoidosis and metastatic malignancy. Further cell subset analysis in these pathologies might additionally reveal immunological distinct cell populations as useful markers to distinguish between sarcoidosis, cancer and the coexistence of these two and help in overcoming the current diagnostic dilemma.

This study was supported by a fellowship from the medical faculty of the University of Münster, Germany to C. Spiekermann.

![PET-CT showing multiple high uptake lesions: 18-Fluorodeoxyglucose positron emission tomography and computed tomography (^18^FDG-PET-CT) of a patient with a history of paranasal sinus adenocarcinoma shows increased uptake of (A) submandibular, (B) cervical, (C) mediastinal and (D) mesenterial lymph nodes suspicious of multiple metastatic lesions. Bioptical examination revealed cervical metastases of the known adenocarcinoma and mediastinal sarcoid-like lesions without malignancy. Courtesy of Professor W. Heindel, Institute of Clinical Radiology, University Hospital Münster. ^18^FDG-PET-CT, 18-fluorodeoxyglucose-positron emission tomography-computed tomography.](ol-14-06-7643-g00){#f1-ol-0-0-7247}

![(A-D) Histological findings of a resected paranasal sinus adenocarcinoma and lymph node. (A) Microphotograph shows the adenocarcinoma with atypical tumor cells (H&E; magnification, ×400) and CDX2 nuclear positive cells, characteristic for intestinal-type adenocarcinoma (inset, H&E, magnification, ×400). (B) Two lymph nodes surrounded by perinodal fat tissue. The right node with noncaseating epitheloid granulomas and the left one with metastatic lesions (H&E, magnification, ×5). (C) Lymph node with noncaseating epitheloid granuloma in higher magnification (H&E, magnification, ×200). Multinuclear giant cells are identifiable. (D) Metastatic carcinoma infiltration in a lymph node (H&E, magnification, ×200). H&E, hematoxylin and eosin; CDX2, caudal type homeobox 2.](ol-14-06-7643-g01){#f2-ol-0-0-7247}

###### 

Characteristics of patients from literature review.

                                     Tumor characteristics   Patient                        Sarcoidosis                                                                                                                                          
  ---------------------------------- ----------------------- ------------------------------ ------------- ------------------------------------ ---- ---- -------------- ----------------- ----------------------------------------------- ------ ----------------------
  Altinkaya *et al*, 2015            Breast                  Ductal invasive carcinoma      T1N0M0        OP                                   70   F    PET            EBUS              LN mediastinal                                  0      ([@b31-ol-0-0-7247])
  Conte *et al*, 2015                Breast                  Ductal invasive carcinoma      pT3pN1        OP                                   50   F    PET            OP+Biopsy         LN pelvic, supradiaphragmatic                   0      ([@b12-ol-0-0-7247])
  Zivin *et al*, 2014                Breast                  Ductal invasive carcinoma      nk            OP                                   32   F    PET            Biopsy+EBUS       LN hilar + mediastinal                          nk     ([@b32-ol-0-0-7247])
  El Hammoumi *et al*, 2015          Breast                  Lobular carcinoma              T1N2Mx        OP + aRCTx (Tamoxifen)               48   F    CT             Biopsy            LN mediastinal                                  36     ([@b11-ol-0-0-7247])
  Kim *et al*, 2014                  Breast                  Ductal invasive carcinoma      T1N2M0        OP + aRCTx                           44   F    PET            Mediastinoscopy   LN paraesophageal, hilar                        24     ([@b33-ol-0-0-7247])
  Akhtari *et al*, 2014              Breast                  Ductal invasive carcinoma      T2N0Mx        OP + aCTx + aRT                      47   F    PET            FNA               LN supraclav., mediastinal, periportal          0      ([@b34-ol-0-0-7247])
  Braza and Nelson, 2014             Breast                  Ductal invasive carcinoma      T1N0M0        nk                                   68   F    MRI            Bone biopsy       Lesions lumbosacral spine                       nk     ([@b35-ol-0-0-7247])
  DeFilippis *et al*,2013            Breast                  Lobular carcinoma              nk            OP + aRTx                            63   F    MRI            Biopsy            LN axillary                                     0      ([@b36-ol-0-0-7247])
  Bush *et al*, 2011                 Breast                  Ductal invasive carcinoma      N0            OP                                   42   F    PET            Biopsy            LN cervical, abdominal, bone, spleen            0      ([@b37-ol-0-0-7247])
  Viswanath *et al*, 2009            Breast                  Ductal invasive carcinoma      T4aN1M0       OP + aRCTx                           50   F    CI             Biopsy            Dermal lesions                                  24     ([@b38-ol-0-0-7247])
  Whittington *et al*, 1986          Breast                  Carcinoma                      N0            nk                                   nk   F    nk             Mediastinoscopy   LN mediastinal                                  0      ([@b39-ol-0-0-7247])
  Whittington *et al*, 1986          Breast                  Carcinoma                      N0            nk                                   nk   F    nk             EBUS              LN hilar                                        0      ([@b39-ol-0-0-7247])
  El Hammoumi *et al*, 2015          Cervix                  Epidermoid Carcinoma           nk            naCTx + OP                           47   F    PET            Mediastinoscopy   LN mediastinal                                  36     ([@b11-ol-0-0-7247])
  Tamauchi *et al*, 2015             Endometrium             Adenocarcinoma                 T1bN0Mx       OP + aCTx                            67   F    CT             OP                LN hilar, paraaortic, pelvine                   0      ([@b40-ol-0-0-7247])
  Powell *et al*, 2005               Endometrium             Adenocarcinoma                 N0            OP                                   67   F    CT             FNA               LN mediastinal, liver lesions                   48     ([@b41-ol-0-0-7247])
  Takanami *et al*, 2008             Esophageal              Squamous cell carcinoma        N0            OP                                   72   M    PET            Biopsy            LN mediastinal + hilar                          −168   ([@b42-ol-0-0-7247])
  Takanami *et al*, 2008             Esophageal              Squamous cell carcinoma        pT1b          OP                                   59   M    PET            Biopsy            LN mediastinal + hilar                          0      ([@b42-ol-0-0-7247])
  Arana *et al*, 2013                Ethmoid sinus           Adenocarcinoma                 T3N0M0        OP + aRCTx                           42   F    PET            Mediastinoscopy   LN mediastinal + hilar                          0      ([@b7-ol-0-0-7247])
  Kachalia *et al*, 2014             Lung                    Adenocarcinoma                 TxNxM2        OP                                   80   F    X-ray          Mediastinoscopy   LN                                              0      ([@b13-ol-0-0-7247])
  Kim *et al*, 2011                  Lung                    Adenocarcinoma                 T2N0M0        OP                                   65   F    PET            Biopsy            LN mediastinal                                  0      ([@b43-ol-0-0-7247])
  Mimura *et al*, 2011               Lung                    Squamous cell carcinoma        pT1N0M0       OP                                   69   M    CT             Biopsy            LN mediastinal                                  −120   ([@b44-ol-0-0-7247])
  Urushiyama *et al*, 2015           Lung                    Squamous cell carcinoma        N0            OP                                   60   M    CT             Biopsy            LN mediastinal + hilar                          −24    ([@b45-ol-0-0-7247])
  Bouaziz *et al*, 2006              Lung                    Squamous cell carcinoma        nk            nk                                   49   M    MRI            EBUS              LN mediastinal, hepatic nodules                 0      ([@b46-ol-0-0-7247])
  Shields *et al*, 2005              Lung                    Papillary carcinoma            M1            OP                                   57   F    PET            Radiology         Salivary and lacrimal glands, LN hilar          0      ([@b14-ol-0-0-7247])
  Sato *et al*, 2003                 Lung                    Adenocarcinoma                 N1            nk                                   nk   nk   nk             Thoracoscopy      LN mediastinal, interlobar                      0      ([@b15-ol-0-0-7247])
  Muramatsu *et al*, 2000            Lung                    Squamous cell carcinoma        N0 M0         OP                                   64   M    CT             Biopsy            LN mediastinal                                  0      ([@b47-ol-0-0-7247])
  Abdel-Galiil *et al*, 2008         Maxilla                 Squamous cell carcinoma        nk            OP                                   51   M    PET            Mediastinoscopy   LN mediastinal+hilar + peribronchial            24     ([@b8-ol-0-0-7247])
  Yao *et al*, 2005                  Oropharynx              Squamous cell carcinoma        T3N2cM0       RCTx                                 49   M    PET            Mediastinoscopy   LN mediastinal, pretracheal, subcarinal         2      ([@b9-ol-0-0-7247])
  Yonenaga *et al*, 2006             Ovar                    Mucinous Cystadenocarcinoma    nk            OP + aCTx                            21   F    PET            nk                Spleen, Liver                                   36     ([@b48-ol-0-0-7247])
  Kim *et al*, 2013                  Ovar                    Papillary cystadenocarcinoma   nk            OP + aCTx                            52   F    PET            EBUS              LN paratracheal, supraclavicular, diaphragmal   12     ([@b49-ol-0-0-7247])
  Pollock and Catalano, 1979         Parotid gland           Ductal carcinoma               N2            OP + aRCTx                           38   M    CI             Biopsy            LN hilar                                        −60    ([@b50-ol-0-0-7247])
  Montini and Tulchinsky, 2012       Rectum                  Cancer                         nk            nk                                   45   M    PET            Biopsy skeletal   LN mediastinal,                                 0      ([@b51-ol-0-0-7247])
  Abdi *et al*, 1987                 Renal                   Renal cell carcinoma           N2            OP + aRTx (IFNα)                     57   F    CT             EBUS              LN mediastinal                                  24     ([@b52-ol-0-0-7247])
  Fukutani *et al*, 1987             Renal                   Renal cell carcinoma           NO            OP                                   75   F    nk             Biopsy            LN pelvic                                       0      ([@b53-ol-0-0-7247])
  Khan and Khan, 1974                Renal                   Hypernephroma                  M1            OP                                   52   M    X-ray          Biopsy            LN hilar                                        0      ([@b19-ol-0-0-7247])
  Gharavi *et al*, 2013              Sacrum                  Chordoma                       nk            OP                                   48   M    PET            Biopsy            LN iliacal + femoral                            12     ([@b54-ol-0-0-7247])
  Wilgenhof *et al*, 2012            Skin                    Melanoma                       M1c           OP + aCTx (Dacarbazine, Cisplatin)   48   F    PET            EBUS              LN hilar                                        84     ([@b55-ol-0-0-7247])
  Vogel *et al*, 2012                Skin                    Melanoma                       N1            OP + aCTx (αCTLA-4)                  49   M    PET            EBUS              LN mediastinal, hilar                           168    ([@b56-ol-0-0-7247])
  Heinzerling *et al*, 2010          Skin                    Melanoma                       pT4N0M0       OP + aCTx (INFα)                     50   M    nk             Biopsy            LN mediastinal                                  7      ([@b57-ol-0-0-7247])
  Chiagne *et al*, 2011              Skin                    Melanoma                       nk            OP                                   35   M    PET            Biopsy            LN inguinal                                     0      ([@b18-ol-0-0-7247])
  Heinzerling *et al*, 2010          Skin                    Melanoma                       pT3bpN1acM0   OP + aCTx (INFα)                     47   M    PET            Biopsy            LN mediastinal+ hilar + peribronchial           nk     ([@b57-ol-0-0-7247])
  Heinzerling *et al*, 2010          Skin                    Melanoma                       N1            OP + aCTx (INFα)                     47   M    PET            Mediastinoscopy   LN mediastinal+ hilar + peribronchial           2      ([@b57-ol-0-0-7247])
  Suarez-Garcia *et al*, 2009        Skin                    Melanoma                       N1            OP + aCTx (INFα)                     42   M    CI             Biopsy            Dermal lesions                                  3      ([@b58-ol-0-0-7247])
  Massaguer *et al*, 2004            Skin                    Melanoma                       nk            CTx (IFNα)                           nk   F    CT             Mediastinoscopy   LN mediastinal                                  nk     ([@b59-ol-0-0-7247])
  Matsubara *et al*, 2015            Stomach                 Adenocarcinoma                 N0            OP                                   64   F    nk             Endoscopy         Gastric sarcoidosis                             −120   ([@b60-ol-0-0-7247])
  El Hammoumi *et al*, 2015          Stomach                 Adenocarcinoma                 nk            OP + aCTx                            59   F    CT             Mediastinoscopy   LN paratracheal                                 36     ([@b11-ol-0-0-7247])
  Tissot *et al*, 1985               Stomach                 Adenocarcinoma                 nk            nk                                   63   F    OP             Biopsy            Combined gastric lesions                        −336   ([@b61-ol-0-0-7247])
  Claus *et al*, 2012                Testis                  Seminoma                       T2N0M1        OP + aCTx (Carboplatin)              34   M    CT             EBUS              LN mediastinal                                  24     ([@b62-ol-0-0-7247])
  Claus *et al*, 2012                Testis                  Seminoma                       T1N0M0        OP + aCTx (Carboplatin)              36   M    CT             Biopsy            LN abdominal                                    0      ([@b62-ol-0-0-7247])
  Teo *et al*, 2013                  Testis                  Seminoma                       T1N2M1a       OP + aCTx (Cisplatin, Etoposid)      20   M    CT             EBUS              LN mediastinal                                  60     ([@b63-ol-0-0-7247])
  Tjan-Heijnen *et al*, 1998         Testis                  Seminoma                       N2            OP + aRTx                            41   M    CT             Mediastinoscopy   LN mediastinal                                  24     ([@b64-ol-0-0-7247])
  Salih *et al*, 2015                Thyroid                 Papillary thyroid carcinoma    T2N1Mx        OP                                   48   F    X-ray          Neck dissection   LN cervical and hilar                           0      ([@b10-ol-0-0-7247])
  Lebo *et al*, 2015                 Thyroid                 Papillary thyroid carcinoma    T1bN1aMx      OP                                   41   F    PET            Mediastinoscopy   Cervical + mediastinal                          0      ([@b16-ol-0-0-7247])
  Myint *et al*, 2015                Thyroid                 Papillary thyroid carcinoma    nk            OP + I-131                           68   F    PET            Bone biopsy       LN hilar + mediast. Bone                        nk     ([@b65-ol-0-0-7247])
  Ergin and Nasr, 2014               Thyroid                 Papillary thyroid carcinoma    N0            OP                                   nk   nk   nk             OP                Cervical                                        pre    ([@b17-ol-0-0-7247])
  Ergin and Nasr, 2014               Thyroid                 Papillary thyroid carcinoma    N0            OP                                   nk   nk   nk             FNA               Cervical                                        post   ([@b17-ol-0-0-7247])
  Ergin and Nasr, 2014               Thyroid                 Papillary thyroid carcinoma    N1            OP                                   nk   nk   PET            OP                Cervical                                        0      ([@b17-ol-0-0-7247])
  Ergin and Nasr, 2014               Thyroid                 Papillary thyroid carcinoma    N0            OP                                   nk   nk   nk             OP                Cervical                                        0      ([@b17-ol-0-0-7247])
  Zimmermann-Belsing *et al*, 2000   Thyroid                 Papillary adenocarcinoma       N2            OP                                   27   M    Scintigraphy   Biospy            LN hilar                                        −36    ([@b66-ol-0-0-7247])

nk, not known; OP, operation; aCTx, adjuvant chemotherapy; aRTx, adjuvant radiotherapy; aRCTx, adjuvant combined radiochemotherapy; naCTx, neoadjuvant chemotherapy; INFα, Interferon alpha; PET, positron emission tomography; CT, computed tomography; F, female; M, male; MRI, magnetic resonance imaging; CI, clinical investigation; EBUS, endobronchial ultrasound based biopsy; FNA, fine needle aspiration; LN, lymph node.
